文献速递消化道肿瘤与早癌消化内镜

萘普生化学预防促进林奇综合征结直肠黏膜免疫激活

Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa.
PubMed 文献 · Gut · 2020-07-08

本研究为Ib期安慰剂对照随机临床试验,80例林奇综合征(LS)患者每日接受萘普生钠440 mg或220 mg共6个月,并联合LS基因工程小鼠模型及患者来源类器官开展协同临床试验。结果显示各组不良事件总数无差异且耐受性良好,萘普生组结直肠黏膜前列腺素E2水平较安慰剂显著降低,并激活不同驻留免疫细胞类型、改变肠隐窝基因表达模式。作者认为萘普生是LS免疫拦截的有前景策略。

要点

  • 萘普生钠440 mg或220 mg每日一次共6个月,各组不良事件总数无差异且耐受性良好。
  • 萘普生组结直肠黏膜前列腺素E2水平较安慰剂显著降低。
  • 萘普生激活不同驻留免疫细胞类型且淋系细胞数量未增加,并改变肠隐窝表达模式。

核心结论

  • 作者认为萘普生是林奇综合征免疫拦截的有前景策略。
  • 研究发现了萘普生诱导的基因表达谱,可能作为预测药物活性的生物标志物。

研究设计与样本

  • Ib期、安慰剂对照、随机临床试验,80例林奇综合征患者每日接受两个剂量水平萘普生钠(440 mg和220 mg)共6个月。
  • 协同临床试验使用林奇综合征基因工程小鼠模型和患者来源类器官(PDO)。
  • 试验注册号:gov标识NCT02052908。

主要发现

  • 总体不良事件总数在各治疗组间无差异,干预耐受性良好。
  • 与安慰剂相比,萘普生治疗后结直肠黏膜前列腺素E2水平显著降低。
  • 萘普生激活不同驻留免疫细胞类型,且淋系细胞数量无任何增加。
  • 萘普生使肠隐窝表达模式向上皮分化和干细胞调控方向改变。
  • 萘普生在小鼠协同临床试验中显示出稳健的化学预防活性;人类中萘普生诱导的基因表达谱可完美区分接受萘普生与对照处理的LS小鼠标本及PDO。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with Lynch syndrome (LS) are at markedly increased risk for colorectal cancer. It is being increasingly recognised that the immune system plays an essential role in LS tumour development, thus making an ideal target for cancer prevention. Our objective was to evaluate the safety, assess the activity and discover novel molecular pathways involved in the activity of naproxen as primary and secondary chemoprevention in patients with LS. DESIGN: We conducted a Phase Ib, placebo-controlled, randomised clinical trial of two dose levels of naproxen sodium (440 and 220 mg) administered daily for 6 months to 80 participants with LS, and a co-clinical trial using a genetically engineered mouse model of LS and patient-derived organoids (PDOs). RESULTS: Overall, the total number of adverse events was not different across treatment arms with excellent tolerance of the intervention. The level of prostaglandin E2 in the colorectal mucosa was significantly decreased after treatment with naproxen when compared with placebo. Naproxen activated different resident immune cell types without any increase in lymphoid cellularity, and changed the expression patterns of the intestinal crypt towards epithelial differentiation and stem cell regulation. Naproxen demonstrated robust chemopreventive activity in a mouse co-clinical trial and gene expression profiles induced by naproxen in humans showed perfect discrimination of mice specimens with LS and PDOs treated with naproxen and control. CONCLUSIONS: Naproxen is a promising strategy for immune interception in LS. We have discovered naproxen-induced gene expression profiles for their potential use as predictive biomarkers of drug activity. TRIAL REGISTRATION NUMBER: gov Identifier: NCT02052908.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Reyes-Uribe L, Wu W, Gelincik O, et al. Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Gut. 2020. PMID: 32641470. doi:10.1136/gutjnl-2020-320946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。